| $376M | ||
| $350M | ||
| $215M | ||
| $127M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $638,337 | 5 | 100 |
| PAKOLA STEVE | Chief Medical Officer | 0 | $0 | 2 | $221,739 | $-221,739 |
| Simpson Curran | Chief Executive Officer | 0 | $0 | 3 | $416,598 | $-416,598 |
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Over the last 12 months, insiders at REGENXBIO Inc. have bought $0 and sold $638,337 worth of REGENXBIO Inc. stock.
On average, over the past 5 years, insiders at REGENXBIO Inc. have bought $0 and sold $2.87M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 175,000 shares for transaction amount of $3.85M was made by Flynn James E (10 percent owner) on 2015‑09‑22.
| 2026-05-11 | Sale | PAKOLA STEVE | Chief Medical Officer | 15,309 0.0324% | $11.02 | $168,705 | -37.20% | |
| 2026-03-10 | Sale | PAKOLA STEVE | Chief Medical Officer | 5,124 0.0101% | $10.35 | $53,033 | -13.43% | |
| 2025-10-09 | Sale | Simpson Curran | Chief Executive Officer | 20,811 0.0427% | $12.62 | $262,635 | -15.20% | |
| 2025-09-29 | Sale | Simpson Curran | Chief Executive Officer | 7,624 0.0154% | $10.03 | $76,469 | +5.58% | |
| 2025-09-10 | Sale | Simpson Curran | Chief Executive Officer | 7,734 0.016% | $10.02 | $77,495 | +5.33% | |
| 2025-05-12 | Sale | Mills Kenneth T. | director | 20,602 0.0408% | $7.91 | $163,046 | +17.44% | |
| 2024-10-01 | Sale | KARABELAS ARGERIS N | director | 10,000 0.0191% | $10.11 | $101,052 | -15.28% | |
| 2024-09-03 | Sale | KARABELAS ARGERIS N | director | 10,000 0.0206% | $11.56 | $115,588 | -23.72% | |
| 2024-08-01 | Sale | Simpson Curran | Chief Executive Officer | 100 0.0002% | $15.00 | $1,500 | -34.26% | |
| 2024-08-01 | Sale | KARABELAS ARGERIS N | director | 10,100 0.0208% | $13.51 | $136,454 | -34.26% | |
| 2024-07-29 | Sale | Simpson Curran | Chief Executive Officer | 9,648 0.0205% | $15.04 | $145,106 | -38.75% | |
| 2024-07-29 | Sale | KARABELAS ARGERIS N | director | 11,000 0.0234% | $15.04 | $165,495 | -38.75% | |
| 2024-07-25 | Sale | Mills Kenneth T. | director | 15,369 0.0303% | $13.96 | $214,501 | -38.53% | |
| 2024-07-24 | Sale | Mills Kenneth T. | director | 12,221 0.0251% | $13.78 | $168,433 | -35.15% | |
| 2024-07-17 | Sale | Mills Kenneth T. | director | 2,210 0.0047% | $13.77 | $30,440 | -32.94% | |
| 2024-07-16 | Sale | Mills Kenneth T. | director | 200 0.0005% | $13.76 | $2,752 | -34.03% | |
| 2024-07-01 | Sale | KARABELAS ARGERIS N | director | 10,000 0.0199% | $11.27 | $112,691 | -16.98% | |
| 2024-05-14 | Sale | Mills Kenneth T. | President and CEO | 15,000 0.0305% | $15.81 | $237,222 | -39.30% | |
| 2024-04-15 | Sale | Mills Kenneth T. | President and CEO | 15,000 0.0309% | $18.19 | $272,871 | -42.45% | |
| 2024-03-14 | Sale | Mills Kenneth T. | President and CEO | 15,000 0.03% | $21.86 | $327,942 | -48.24% |
| PAKOLA STEVE | Chief Medical Officer | 232617 0.45% | $1.46M | 0 | 6 | |
| Simpson Curran | Chief Executive Officer | 216162 0.4181% | $1.36M | 0 | 23 | |
| Fox Allan M. | 1529981 2.9595% | $9.61M | 0 | 3 | ||
| Flynn James E | 10 percent owner | 1256542 2.4306% | $7.89M | 1 | 0 | <0.0001% |
| FMR LLC | 619376 1.1981% | $3.89M | 0 | 25 | ||
| Mills Kenneth T. | director | 475103 0.919% | $2.98M | 0 | 57 | |
| Vasista Vittal | Chief Financial Officer | 135160 0.2614% | $848,804.80 | 0 | 48 | |
| Christmas Patrick J. | 16372 0.0317% | $102,816.16 | 0 | 19 | ||
| KARABELAS ARGERIS N | director | 11286 0.0218% | $70,876.08 | 0 | 5 | |
| Danos Olivier | 6500 0.0126% | $40,820.00 | 0 | 2 | ||
| BESHAR LUKE M | 0 0% | $0 | 0 | 5 | ||
| HAYDEN DONALD J JR | 0 0% | $0 | 0 | 18 | ||
| Yoo Stephen | 0 0% | $0 | 0 | 11 |
$6,125,624 | 95 | -6.06% | $338.04M | |
$60,836,085 | 69 | 0.45% | $319.1M | |
$8,587,568 | 37 | 47.91% | $315.52M | |
$63,049,419 | 31 | 2.87% | $329.81M | |
$22,017,898 | 24 | 39.19% | $358.07M | |
$3,668,031 | 23 | 2.05% | $315.18M | |
$15,467,825 | 18 | 4.98% | $366.83M | |
$1,447,973 | 17 | 13.95% | $308.17M | |
$101,822,203 | 13 | 84.03% | $321.58M | |
$176,565 | 8 | -2.61% | $355.76M | |
$747,947 | 6 | 10.18% | $320.14M | |
$556,839 | 5 | 13.42% | $320.54M | |
$51,688 | 4 | -26.18% | $365.96M | |
$208,592 | 4 | 11.22% | $318.26M | |
$184,294 | 3 | -10.64% | $348.92M | |
$10,104,842 | 3 | 5.45% | $329.79M | |
$37,067 | 3 | -89.81% | $308.97M | |
$20,020,000 | 1 | -75.24% | $344.64M | |
REGENXBIO Inc. (RGNX) | $3,850,000 | 1 | -51.32% | $324.66M |
| Increased Positions | 89 | +48.9% | 4M | +9.5% |
| Decreased Positions | 77 | -42.31% | 4M | -9.46% |
| New Positions | 28 | New | 1M | New |
| Sold Out Positions | 15 | Sold Out | 713,601 | Sold Out |
| Total Postitions | 194 | +6.59% | 42M | +0.04% |
| Blackrock, Inc. | $86,453.00 | 12.49% | 6.37M | -388,200 | -5.74% | 2025-09-30 |
| Redmile Group, Llc | $63,689.00 | 9.2% | 4.69M | -82,328 | -1.72% | 2025-09-30 |
| Jpmorgan Chase & Co | $54,785.00 | 7.92% | 4.04M | +185,223 | +4.81% | 2025-09-30 |
| Vanguard Group Inc | $45,298.00 | 6.55% | 3.34M | -83,094 | -2.43% | 2025-09-30 |
| State Street Corp | $26,935.00 | 3.89% | 1.98M | +141,233 | +7.66% | 2025-09-30 |
| Goldman Sachs Group Inc | $25,135.00 | 3.63% | 1.85M | +67,708 | +3.79% | 2025-09-30 |
| Morgan Stanley | $23,127.00 | 3.34% | 1.7M | +709,512 | +71.33% | 2025-09-30 |
| Aqr Capital Management Llc | $17,501.00 | 2.53% | 1.29M | +359,459 | +38.64% | 2025-09-30 |
| Geode Capital Management, Llc | $15,274.00 | 2.21% | 1.13M | -2,973 | -0.26% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $14,995.00 | 2.17% | 1.11M | -17,736 | -1.58% | 2025-09-30 |